Interleukin-38 Levels in Individuals With Periodontitis
Study Details
Study Description
Brief Summary
Interleukin (IL)-38 is the newest member of the IL-1 family. It can bind to receptors through various pathways and regulate the formation and function of inflammatory cytokines. Periodontitis is a chronic inflammatory disease that can start with localized inflammatory reactions created by the supporting tissues surrounding the teeth against microorganisms and then result in loss of teeth. The aim of this study is to compare the IL-38, IL-1β and IL-10 levels of healthy and periodontitis individuals.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Periodontitis is a destructive chronic inflammatory disease that can start with localized inflammatory reactions created by the supporting tissues surrounding the teeth against microorganisms and then result in loss of teeth. More than any other cytokine family, the interleukin (IL)-1 family (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL-36γ, IL-1Ra, IL-36Ra, IL-37, IL-38) includes key signaling molecules that trigger and perpetuate periodontal inflammation.
Interleukine -1β ( IL-1β ) levels are associated with periodontal destruction in the pathogenesis of periodontal disease. Interleukine-10 (IL-10) has been reported to decrease periodontal disease progression rate.
Gingival crevicular fluid shows the cellular response in the periodontium. The most important host-related ingredients are inflammatory markers, including cytokines, enzymes, and interleukins. Saliva analysis is used in the diagnosis of systemic conditions as well as in the diagnosis of oral pathologies.
In recent studies, IL-38 expression has been reported to be abnormal (abnormal) in chronic inflammatory diseases, especially in rheumatoid diseases such as systemic lupus erythematosus, rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Therefore, this relationship of this inflammatory cytokine with chronic inflammatory diseases draws attention to the regulatory effect of IL-38 in these diseases. The aim of this study is to compare the IL-38, IL-1β and IL-10 levels of healthy and periodontitis individuals.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Periodontitis Individuals with Periodontitis |
Other: Saliva
individuals' saliva samples will be collected and transferred to eppendorf tubes.
Until biochemical analysis is carried out will be stored in -80ºC.
Other Names:
Other: gingival crevicular fluid
GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
Other Names:
|
| Gingivitis Individuals with Gingival Inflammation |
Other: Saliva
individuals' saliva samples will be collected and transferred to eppendorf tubes.
Until biochemical analysis is carried out will be stored in -80ºC.
Other Names:
Other: gingival crevicular fluid
GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
Other Names:
|
| Healthy Individuals with Periodontally Healthy |
Other: Saliva
individuals' saliva samples will be collected and transferred to eppendorf tubes.
Until biochemical analysis is carried out will be stored in -80ºC.
Other Names:
Other: gingival crevicular fluid
GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- IL-38 levels [initial examination, baseline]
saliva and DOS levels
- IL-1β levels [initial examination, baseline]
saliva and DOS levels
- IL-10 levels [initial examination, baseline]
saliva and DOS levels
Secondary Outcome Measures
- Plaque Index [initial examination, baseline]
Silness-Löe
- Probing Depth [initial examination, baseline]
millimeter
- Bleeding on Probe [initial examination, baseline]
Ainamo&Bay
Eligibility Criteria
Criteria
Inclusion Criteria:
-
systemically healthy individuals who does not have a disease under treatment,
-
individuals without regular systemic medication
Exclusion Criteria:
-
smoking
-
receiving periodontal treatment in the last 6 months
-
pregnancy
-
lactation
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Saglik Bilimleri Universitesi | İstanbul | Turkey |
Sponsors and Collaborators
- Saglik Bilimleri Universitesi
Investigators
- Principal Investigator: Ayşe Toraman, Dr, Saglik Bilimleri Universitesi
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IstanbulSBU